Healthcare / Health Information ServicesHKSE
$1.65
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-27.1M · quality 56.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$448M
P/E
33.0x
↑EV/EBITDA
N/A
•ROE
-63.6%
↓Gross Margin
15.9%
↓Debt/Equity
0.67
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-23.1%
FCF CAGR
—
FCF margin
-8.4%
FCF / Net income
0.60x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $321.6M · net income $-45.2M · FCF $-27.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $321.6M | $321.6M | $331.3M | $323.4M | $708.4M |
| Net Income | $-45.2M | $-45.2M | $-94.1M | $-89.2M | $4.6M |
| EBITDA | $-33.7M | $-33.7M | $-74.5M | $-69.1M | $26.3M |
| EPS | -23.63 | -23.63 | -0.49 | -0.48 | 0.03 |
| Gross Margin | 15.9% | 15.9% | 9.0% | 10.1% | 13.2% |
| Operating Margin | -8.1% | -8.1% | -22.0% | -28.1% | -0.3% |
| Net Margin | -14.1% | -14.1% | -28.4% | -27.6% | 0.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.67 | 0.67 | 0.27 | 0.14 | 0.09 |
| Current Ratio | 1.89 | 1.89 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-27.1M | $-27.1M | $-77.2M | $-22.8M | $-24.7M |
| Returns | |||||
| ROE | -63.6% | -63.6% | -81.0% | -45.7% | 1.6% |
| Valuation | |||||
| P/E | 33.00 | 33.00 | — | — | 50.59 |
| EV/EBITDA | — | — | — | — | 3.60 |
| P/B | 4.44 | 4.44 | 0.77 | 1.24 | 0.83 |
| Growth & Yield | |||||
| Revenue Growth | -2.9% | -2.9% | 2.5% | -54.3% | — |
| EPS Growth | -4707.7% | -4707.7% | -2.4% | -1982.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+275.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.49 → -23.63
Residual
+275.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.